Private Wealth Partners LLC lifted its stake in Bristol-Myers Squibb Company (NYSE:BMY) by 20.1% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 8,350 shares of the biopharmaceutical company’s stock after acquiring an additional 1,400 shares during the period. Private Wealth Partners LLC’s holdings in Bristol-Myers Squibb were worth $465,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of BMY. Nisa Investment Advisors LLC raised its stake in shares of Bristol-Myers Squibb by 1.8% in the 1st quarter. Nisa Investment Advisors LLC now owns 610,253 shares of the biopharmaceutical company’s stock valued at $33,186,000 after acquiring an additional 10,541 shares in the last quarter. Quantitative Systematic Strategies LLC raised its stake in shares of Bristol-Myers Squibb by 447.5% in the 1st quarter. Quantitative Systematic Strategies LLC now owns 32,128 shares of the biopharmaceutical company’s stock valued at $1,747,000 after acquiring an additional 26,260 shares in the last quarter. Hartford Financial Management Inc. raised its stake in shares of Bristol-Myers Squibb by 1.8% in the 1st quarter. Hartford Financial Management Inc. now owns 69,247 shares of the biopharmaceutical company’s stock valued at $3,765,000 after acquiring an additional 1,223 shares in the last quarter. Ledyard National Bank raised its stake in shares of Bristol-Myers Squibb by 25.5% in the 1st quarter. Ledyard National Bank now owns 27,248 shares of the biopharmaceutical company’s stock valued at $1,482,000 after acquiring an additional 5,533 shares in the last quarter. Finally, Bollard Group LLC raised its stake in shares of Bristol-Myers Squibb by 7.8% in the 1st quarter. Bollard Group LLC now owns 186,473 shares of the biopharmaceutical company’s stock valued at $10,140,000 after acquiring an additional 13,425 shares in the last quarter. 68.88% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Bristol-Myers Squibb Company (BMY) Position Lifted by Private Wealth Partners LLC” was first published by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/09/20/bristol-myers-squibb-company-bmy-position-lifted-by-private-wealth-partners-llc.html.

A number of brokerages recently weighed in on BMY. Cowen and Company reissued a “hold” rating and issued a $65.00 price objective on shares of Bristol-Myers Squibb in a research note on Tuesday. BidaskClub raised Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research report on Saturday, August 12th. Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and issued a $63.00 price target on shares of Bristol-Myers Squibb in a research report on Wednesday, August 9th. Vetr raised Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $64.08 price target on the stock in a research report on Thursday, August 17th. Finally, William Blair reaffirmed an “outperform” rating on shares of Bristol-Myers Squibb in a research report on Monday, June 26th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company. Bristol-Myers Squibb currently has a consensus rating of “Hold” and an average price target of $62.66.

In other news, SVP Joseph C. Caldarella sold 9,340 shares of the stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total transaction of $560,400.00. Following the transaction, the senior vice president now owns 46,297 shares in the company, valued at $2,777,820. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Theodore R. Samuels II purchased 6,000 shares of Bristol-Myers Squibb stock in a transaction that occurred on Wednesday, August 2nd. The shares were bought at an average cost of $55.94 per share, for a total transaction of $335,640.00. Following the transaction, the director now directly owns 18,000 shares of the company’s stock, valued at $1,006,920. The disclosure for this purchase can be found here. 0.23% of the stock is currently owned by company insiders.

Shares of Bristol-Myers Squibb Company (BMY) opened at 62.93 on Wednesday. The firm has a market cap of $103.20 billion, a price-to-earnings ratio of 22.98 and a beta of 1.18. The stock’s 50 day moving average price is $58.94 and its 200 day moving average price is $56.02. Bristol-Myers Squibb Company has a one year low of $46.01 and a one year high of $63.47.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.73 by $0.01. The company had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.09 billion. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The firm’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same quarter last year, the company earned $0.69 earnings per share. On average, equities analysts anticipate that Bristol-Myers Squibb Company will post $2.98 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, November 1st. Stockholders of record on Friday, October 6th will be paid a dividend of $0.39 per share. The ex-dividend date of this dividend is Thursday, October 5th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 2.48%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 56.73%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.